Eric TopolSep 24, 2023

The breakthrough class of GLP-1 and G-Agonist Drugs are exceeding lofty expectations beyond weight loss. Why?

https://erictopol.substack.com/p/when-the-breakthrough-g-agonists

When the Breakthrough Obesity G-Agonist Drugs Exceed Expectations

The expanding GLP-1 family of drugs and their expanded potential use cases

Ground Truths
Show threadKarl Schwartz, Artist advocate

@erictopol

Very interesting.

How do you see the design of phase 3 studies for these study drugs?

Study size?
The comparator?
The primary endpoints?

Would it have to include All cause Survival for unknown bad effects?

Sep 25, 2023 at 12:54pmWeb